CN Patent

CN103945831A — 医药制剂

Assigned to Novartis AG · Expires 2014-07-23 · 12y expired

What this patent protects

本发明涉及(S)-甲基(1-((4-(3-(5-氯-2-氟-3-(甲基磺酰氨基)苯基)-1-异丙基-1H-吡唑-4-基)嘧啶-2-基)氨基)丙-2-基)氨基甲酸酯(化合物A)的固体口服医药制剂，和这些制剂于治疗增殖性疾病，例如实体肿瘤疾病，的用途。

USPTO Abstract

本发明涉及(S)-甲基(1-((4-(3-(5-氯-2-氟-3-(甲基磺酰氨基)苯基)-1-异丙基-1H-吡唑-4-基)嘧啶-2-基)氨基)丙-2-基)氨基甲酸酯(化合物A)的固体口服医药制剂，和这些制剂于治疗增殖性疾病，例如实体肿瘤疾病，的用途。

Drugs covered by this patent

Braftovi (encorafenib) · Pfizer

Patent Metadata

Patent number: CN103945831A
Jurisdiction: CN
Classification: —
Expires: 2014-07-23
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.